Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Richard Paine

  • Home
  •  
  • Richard Paine



  • Most Read
  • Latest Comments
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • News

  • Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits
    Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits
    • News

  • Bubs goes full steam ahead with US FDA trials in rising market for infant formula
    Bubs goes full steam ahead with US FDA trials in rising market for infant formula
    • News

  • Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    • News

  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    Bubs enrols 400th infant in its US clinical trials to get baby formula approval

    Under its old business model, the number 4 would typically never be marketed to their major customers but under the new direction of infant formula company Bubs Australia (ASX: BUB), its a joyous occasion with the 400th infant enrolled in their clinical trial program which seeks regulatory approval for commercial sales in the United States. 

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.